CytomX Therapeutics Inc  

(Public, NASDAQ:CTMX)   Watch this stock  
Find more results for CTMX
-0.18 (-1.24%)
Real-time:   2:47PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 14.23 - 14.83
52 week 9.10 - 20.02
Open 14.53
Vol / Avg. 85,748.00/195,642.00
Mkt cap 509.42M
P/E     -
Div/yield     -
EPS -1.41
Shares 36.75M
Beta     -
Inst. own 84%
Aug 1, 2017
Q2 2017 CytomX Therapeutics Inc Earnings Release (Estimated) Add to calendar
Jun 7, 2017
CytomX Therapeutics Inc at Jefferies Healthcare Conference - 3:30PM EDT - Add to calendar
May 5, 2017
Q1 2017 CytomX Therapeutics Inc Earnings Release
Mar 20, 2017
CytomX Therapeutics Bristol-Myers Squibb Collaboration Expansion Conference Call
Mar 15, 2017
CytomX Therapeutics Inc at Barclays Global Healthcare Conference
Mar 6, 2017
CytomX Therapeutics Inc at Cowen Health Care Conference
Mar 2, 2017
Q4 2016 CytomX Therapeutics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '17) 2016
Net profit margin -70.86% -391.54%
Operating margin -73.92% -396.10%
EBITD margin - -384.58%
Return on average assets -17.57% -29.72%
Return on average equity -43.50% -57.59%
Employees 78 -
CDP Score - -


151 Oyster Point Blvd Ste 400
United States - Map
+1-650-5153185 (Phone)
+1-650-3510353 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies. Its product candidates include CX-072, CX-2009, CX-2029, Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and CX-188. Its Probody platform utilizes active proteases in tumor tissue to allow monoclonal antibody-based therapies. Its investigational Probody therapeutics address clinically validated cancer targets in immuno-oncology, such as programmed death-ligand 1, against which CX-072 is directed, as well as targets, such as cluster of differentiation 166, against, which CX-2009 is directed.

Officers and directors

Hoyoung Huh Ph.D. Chairman of the Board
Age: 46
Bio & Compensation  - Reuters
Sean A McCarthy Ph.D. President, Chief Executive Officer, Director
Age: 48
Bio & Compensation  - Reuters
Debanjan Ray Chief Financial Officer, Principal Financial and Accounting Officer
Age: 39
Bio & Compensation  - Reuters
Cynthia Jane Ladd Senior Vice President, General Counsel
Age: 60
Bio & Compensation  - Reuters
W. Michael Kavanaugh M.D. Chief Scientific Officer and Head - Research and Non-Clinical Development
Age: 59
Bio & Compensation  - Reuters
Rachel W. Humphrey M.D. Chief Medical Officer
Age: 54
Bio & Compensation  - Reuters
Marion McCourt Director
Bio & Compensation  - Reuters
John A. Scarlett M.D. Director
Age: 65
Bio & Compensation  - Reuters
Neil Exter Independent Director
Bio & Compensation  - Reuters
Frederick Gluck Independent Director
Age: 80
Bio & Compensation  - Reuters